Ivana von Metzler

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma

O. Sezer, C. Assaf, M. Mieth, 2009, European journal of haematology.

Synergistic action of the novel HSP90 inhibitor NVP‐AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma

P. Atadja, M. Jensen, C. García-echeverría, 2010, European journal of haematology.

BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma

P. Kloetzel, O. Sezer, U. Kuckelkorn, 2010, European Journal of Haematology.

Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib.

O. Sezer, M. Kaiser, L. Kleeberg, 2010, Clinical lymphoma, myeloma & leukemia.

Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.

O. Sezer, M. Mieth, M. Kaiser, 2009, Experimental cell research.

Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA).

O. Sezer, M. Kaiser, M. Hecht, 2008, Experimental cell research.

The novel, orally bioavailable HSP90 inhibitor NVP‐HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases

M. Jensen, O. Sezer, M. Mieth, 2012, European journal of haematology.